Biliary tract cancer (BTC) is an uncommon and heterogeneous tumour family with poor prognosis. Surgery represents the only curative option for these patients in less than 25% of the cases and the relapse rate is high ([@bib5]). The majority of these patients have advanced disease (metastatic or unresectable) at diagnosis and median overall survival (OS) rarely exceeds 6--8 months ([@bib4]). In this scenario, palliative treatment aims at improving quality of life and OS. In particular, in randomised phase III trials systemic chemotherapy (CT) was associated with a significant benefit in terms of quality and length of life compared with best supportive care alone ([@bib7]; [@bib12]). Subsequently, two randomised studies identified the cisplatin plus gemcitabine regimen as the standard first-line CT ([@bib10]; [@bib14]): in these trials, OS was 11.7 and 11.2 months in the combination arm *vs* 8.1 and 7.7 months for single agent CT (*P*\<0.001), respectively. The combination of gemcitabine and oxaliplatin is another regimen which resulted active and well tolerated in prospective trials in BTC, and it is thus largely used in clinical practice ([@bib1]).

Up to 50% of BTC patients failing standard first-line therapy maintain a good performance status (PS) and remain eligible for further treatment ([@bib3]). Nevertheless, clinical trials focused on second-line therapy are difficult to perform due to the rarity of these tumours and the heterogeneity of patient population, which is generally characterised by refractoriness to platinum compounds and gemcitabine. So, in the absence of randomised studies, only limited and disappointing data regarding second-line CT regimens and biologic agents are available in the literature with objective response rates (RRs) of 0--23% and median progression-free survival (PFS) times not exceeding 4 months ([@bib6]; [@bib8]; [@bib2]; [@bib3]; [@bib15]). Furthermore, identification of predictive or prognostic factors able to identify patients who could benefit from second-line therapy is a clinical issue ([@bib8]; [@bib3]; [@bib15]).

Herein, we report the results of the largest survey evaluating the clinical practice of several Italian oncologic centres in the treatment of patients with advanced BTCs (aBTCs) relapsed or progressed after a first-line treatment strategy.

Materials and Methods
=====================

Patients and methods
--------------------

We retrospectively identified patients with aBTCs treated with second-line CT at 10 Italian Institutions between 2004 (when initial data with gemcitabine plus a platinum derivative such as oxaliplatin as first-line CT were published ([@bib1])) and 2013. Criteria for case inclusion were: cyto-histologically confirmed diagnosis of non-resectable, recurrent or metastatic biliary tract adenocarcinoma (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder and ampullary carcinoma); age ⩾18 years; confirmed progression after first-line CT, administered until disease progression, unacceptable toxicity, patient refusal or for a maximum of 6 months of treatment; availability of clinico-pathological and laboratory features at the beginning of second-line CT and subsequent response evaluation and survival data. All the patients fulfilling the abovementioned criteria were included in the analyses, independently of the first- and second-line CT regimens received.

Factors included in the univariate analyses for PFS and OS were the following: age; sex; Eastern Cooperative Oncology Group (ECOG) PS (0 *vs* 1--2); tumour location (intrahepatic *vs* extrahepatic *vs* gallbladder *vs* ampullary); surgery on primary tumour; disease extent (locally advanced *vs* metastatic); number of disease sites; presence of liver, lung, peritoneal or bone metastases; first-line CT containing gemcitabine and a platinum derivative; objective response and PFS after first-line CT; carcinoembrionic antigen and carbohydrate antigen 19.9 (CA19.9) levels; haematologic parameters (i.e. haemoglobin, white cell count and platelet count); serum albumin; transaminases (alanine aminotransferase and aspartate aminotransferase); alkaline phosphatase; total bilirubin; weight loss \>5% before second-line CT. Laboratory variables were initially recorded as continuous variables and later dichotomised according to the median value of each variable. Haematologic parameters were dichotomised using local laboratory values to define anaemia (12 g dl^−1^), leukocytosis (10 000 mm^−3^) and thrombocytosis (400 000 mm^−3^). The threshold of 70 years of age was used to identify elderly patients. PFS after first-line CT was measured from the date of treatment beginning to the date of progression; to accurately evaluate the association of first-line PFS with OS after second-line CT, this variable was dichotomised, too, using as cut-off point the median first-line PFS of the entire study population.

All the patients included provided written informed consent before treatment initiation, allowing treating physicians to administer the proposed second-line CT, perform laboratory analyses and collect all the data in a site-specific database. The different data sets from each centres have been later merged and information shared among centres, assuring patient anonymisation.

Statistical analysis
--------------------

The primary end point of this retrospective analysis was OS. OS was measured from the date of the first cycle of second-line CT to the date of death or last follow-up visit. Secondary end points were: objective tumour response, evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.0 ([@bib13]) (imaging was repeated every 10 weeks until disease progression) and PFS (measured from the date of the first cycle of second-line CT to the date of disease progression or death, whichever occurred first). PFS and OS were estimated using the Kaplan--Meier product-limit method.

For both second-line PFS and OS, we initially performed a univariate assessment of the prognostic effect of each factor, comparing survival curves by the use of the log-rank test. In order to account for multiple testing, a two-sided *P*-value of \<0.005 was considered significant at univariate analysis. Multivariate analysis was then carried out using stepwise Cox proportional hazards regression modelling, stratifying for the second-line CT regimens received (monotherapy *vs* combination CT) and setting statistical significance at *P*\<0.05 for a two-sided test. Statistical analyses were carried out using the statistical software package SPSS 19.0 (SPSS, Chicago, IL, USA).

Results
=======

Patients
--------

Of the 811 patients starting first-line CT, 357 patients (44%) were treated with second-line CT from 04 March 2004 to 10 April 2013. Three hundred patients (37%) fulfilled all the abovementioned criteria and were therefore included in the analysis. Patient characteristics are summarised in [Table 1](#tbl1){ref-type="table"}. Fifty-two percent of patients had an intrahepatic cholangiocarcinoma, 21% had an extrahepatic cholangiocarcinoma, whereas gallbladder and ampullary carcinoma were recorded in 18 and 9% of the cases, respectively. More than a half (64%) of patients received a first-line gemcitabine plus platinum (either oxaliplatin or cisplatin) combination: with regard to first-line therapy, partial response was reported in 55 patients (18% RR: 18%), whereas median PFS was 6.0 months.

Second-line treatment outcome
-----------------------------

Second-line CT regimens are listed in [Table 1](#tbl1){ref-type="table"}. Among the 293 evaluable patients, 12 (4%) partial responses (RR: 4%) and 88 (30%) disease stabilisations have been observed, for a disease control rate (DCR) of 34%. At the time of the analysis, 270 patients (90%) had progressed and median PFS was 3.2 months (95% confidence interval (CI): 2.9--3.5).

We exploratory investigated factors associated with better outcome in terms of objective response and PFS with second-line CT. In particular, we queued whether different second-line CT regimens achieved different outcome, and found that the use of combination regimens seemed associated with higher DCR compared with monotherapy (39% *vs* 26% *P*=0.030) as well as longer median PFS (3.4 *vs* 3.0 months; hazard ratio (HR), 0.688; 95% CI 0.504--0.850; *P*=0.002) and OS (8.2 *vs* 5.2 months; HR, 0.718; 95% CI 0.535--0.964; *P*=0.028). At univariate analysis, factors associated with longer PFS were: ECOG PS 0 (*P*\<0.001), locally advanced disease (*P*=0.001), first-line PFS ⩾6 months (*P*=0.004), CA19.9 ⩽152 U ml^−1^ (*P*\<0.001) and WBC count ⩽10 000 mm^−3^ (*P*\<0.001) ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). When tested at multivariate analysis, stratifying for the second-line CT received, the following parameters retained statistical significance as good prognostic factors: WBC count ⩽10 000 mm^−3^ (*P*=0.029; HR, 0.659; 95% CI 0.454--0.957), ECOG PS 0 (*P*=0.030; HR, 0.701; 95% CI 0.509--0.965), CA19.9 ⩽152 U ml^−1^ (*P*=0.028; HR, 0.726; 95% CI 0.545--0.966) and first-line PFS ⩾6 months (*P*=0.040; HR, 0.748; 95% CI 0.567--0.987).

Multivariate prognostic model
-----------------------------

At the time of the analysis, 224 patients (75%) have died and median OS from the beginning of second-line CT for the entire population was 7.2 months (95% CI: 6.0--8.4) ([Figure 1A](#fig1){ref-type="fig"}).

At univariate analysis ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}), 10 variables were significantly associated with longer OS: ECOG PS 0 (*P*\<0.001), site of primary tumour (*P*=0.003), surgery on primary tumour (*P*\<0.001), first-line PFS ⩾6 months (*P*=0.003), CA19.9 ⩽152 U ml^−1^ (*P*\<0.001), haemoglobin ⩽12 g dl^−1^ (*P*=0.001), WBC count ⩽10 000 mm^−3^ (*P*\<0.001), serum albumin ⩽3.56 g dl^−1^ (*P*\<0.001), alkaline phosphatase ⩽247 U l^−1^ (*P*=0.004) and weight loss \>5% (*P*\<0.001).

Multivariate regression analysis ([Table 2](#tbl2){ref-type="table"}) was therefore conducted including all the abovementioned parameters, stratifying for the second-line CT received. Independent, favourable prognostic factors were: an ECOG PS of 0 (*P*\<0.001; HR, 0.348; 95% CI 0.215--0.562), CA19.9 ⩽152 U ml^−1^ (*P*=0.013; HR, 0.574; 95% CI 0.370--0.891), previous surgery on primary tumour (*P*=0.027; HR, 0.609; 95% CI 0.392--0.945) and PFS after first-line CT ⩾6 months (*P*=0.027; HR, 0.633; 95% CI 0.422--0.949).

We depicted a multivariate prognostic model by combining these four independent prognostic factors according to the following criteria: good-risk group, that is, patients with zero to one negative prognostic factors; intermediate-risk group, that is, patients with two negative prognostic factors; poor-risk group, that is, patients with three to four negative prognostic factors. Of 249 patients with complete data for the four variables, 98 patients were categorised as good-risk group, 73 patients as intermediate-risk group and 78 patients as poor-risk group. The survival curves according to the prognostic model are provided in [Figure 1B](#fig1){ref-type="fig"}. Median OS for good-, intermediate- and poor-risk groups were 13.1 months (95% CI 9.0--17.2), 6.6 months (95% CI 5.2--8.0) and 3.7 months (95% CI 3.0--4.4), respectively. Survival differences among groups achieved statistical significance (*P*\<0.001).

Discussion
==========

Second-line treatment of aBTC represents a great challenge: consistent evidence of a survival benefit for palliative CT is lacking, and thus no standard regimen is available in clinical practice ([@bib3]). The current analysis identified several reliable prognostic factors in this setting. Of note, as it is based on easily available variables, this model has the potentials for widespread use.

To our knowledge, we collected the so far largest series of aBTC patients treated with second-line CT since 2004, when the results of the GEMOX regimen were published ([@bib1]). Our population is therefore enriched with patients treated with a platinum plus gemcitabine combination in first-line, which is considered the standard approach after the publication of the ABC-02 and BT trials ([@bib10]; [@bib14]). Results of first-line CT are in line with literature data both in terms of DCR and PFS, thus reassuring about the risk of major selection bias in case collection. Our series confirms that almost half of aBTC cases received second-line therapy and that CT has only marginal activity (RR: 4%) in pretreated patients, even though it may offer disease control in up to 34% of the cases. By the identification of four clinical and laboratory parameters such as ECOG PS, basal CA19.9 level, previous surgery on primary tumour and first-line PFS, three patient subgroups with different survival outcome can be identified. The OS curves for these risk groups are comparable with those reported by [@bib11] in the first-line setting, suggesting that the magnitude of benefit of salvage treatment is predictable, too.

PS confirmed to be the most important prognostic determinant even in pretreated aBTC patients. This observation is in line with other reports in the first- and second-line setting ([@bib11]; [@bib2]; [@bib3]). As aBTC is a rapidly progressing disease, which may impact on patients\' general condition and liver function, an accurate evaluation of pretreatment PS is essential before any therapeutic decision.

The prognostic value of CA19.9 in our series is apparently in contrast with the results reported in first-line ([@bib11]). As the expression of tumour markers widely varies among patients, this discrepancy may be partly explained by different patient populations. CA19.9 is a proven prognostic factor in other gastrointestinal malignancies such as gastric and pancreatic cancer, and our data are in line with these experiences. As we did not find a significant impact of the number of metastatic sites on OS, higher CA19.9 levels may not only reflect a higher tumour burden, but also a more aggressive tumour behaviour.

The positive prognostic role of previous surgery on primary tumour is probably linked to a more favourable disease course in patients presenting with resectable tumour; in fact, biology may differ in localised and unresectable or metastatic disease at diagnosis. Moreover, immediate surgery may avoid otherwise frequent complications in aBTC such as biliary or bowel obstruction, thus favourably impacting on patient conditions and treatment tolerability.

[@bib15] reported in a smaller series that PFS after first-line CT is a predictor of benefit from second-line therapy in terms of PFS; however, they did not analyse OS or integrate this parameter into a prognostic score. Similarly, [@bib8] found that response to first-line CT is an independent predictor of OS with salvage therapy in their series of 89 cases. Even though the formal demonstration that PFS is a surrogate for OS in aBTC is lacking, it is arguable that PFS may represent an index of the chemosensitivity of the disease. Therefore, no or limited benefit from first-line CT should discourage from an aggressive approach in second-line. The threshold of 6 months for the PFS variable appears a reasonable choice, as reported median PFS times with first-line platinum plus gemcitabine regimens are in the range 5.7--8.0 months ([@bib10]; [@bib14]; [@bib6]).

Our retrospective study did not aim to identify an optimal second-line CT regimen. Univariate analysis suggests that combination CT is associated with a slightly higher DCR compared with monotherapy (39% *vs* 26% *P*=0.002) as well as slightly longer median PFS (3.4 *vs* 3.0 months; *P*=0.030), as reported also by [@bib15], and OS (8.2 *vs* 5.2 months; *P*=0.028). We thus selected the second-line CT regimen as a stratification factor at multivariate analysis, in order to develop a prognostic model based only on baseline treatment-independent, patient- and disease-related factors. Therefore, caution is needed and randomised trials are ongoing in order to establish the optimal second-line regimen in aBTC ([@bib3]). In our opinion, until the results of these trials are made available, the use of combination CT is justified in those patients with good PS and preserved liver function who derived significant benefit from first-line CT (e.g., objective response and PFS longer than 6 months) without major toxicities. This simple prognostic model may thus help in designing and interpreting the results of future trials.

Our analysis confirms that it is unlikely that CT alone could have a dramatic impact on aBTC prognosis. There is, therefore, an urgent need for the identification of molecular targets and effective targeted agents in this setting. Little is known about the molecular basis of aBTC, a wide-spectrum category, which comprises different entities such as cholangiocarcinoma, gallbladder and ampullary cancer. Up to now, several phase II studies evaluated different agents with conflicting results ([@bib3]; [@bib9]). In the absence of any treatment individualisation strategy by means of biologic predictive factors, the road toward any improvement in patient outcome appears still too long and windy, and notwithstanding even more necessary. With this regard, it should be kept in mind that the current analysis is based on patients treated with different CT regimens only; therefore, conclusions may not be valid in patients treated with biologics.

In conclusion, our model is based on some easily available clinical and laboratory factors, which reliably identify different groups of aBTC patients with different outcome after second-line CT. If validated in other data sets, these results may represent a useful tool for individual patient-risk evaluation and trial design and interpretation. Results of phase III randomised trials comparing different second-line single agent and combination CT after the failure of a platinum plus gemcitabine regimen are eagerly awaited. Finally, further research on the biologic landscape of BTC and the development of targeted agents are highly warranted in order to move forward the therapeutic armamentarium against this aggressive disease.
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![**Survival curves for all patients (**A**) and according to the risk groups identified at multivariate analysis (**B**).** Abbreviations: *N*=number; OS=overall survival.](bjc2014190f1){#fig1}

###### Patient characteristics (*N*=300)

                                                        ***N* (%)**
  ----------------------------------------------------- -------------------
  Age, years (median, range)                            64 (28--85)
  **Gender**                                            
  Female                                                136 (45%)
  Male                                                  164 (55%)
  **ECOG performance status**                           
  0                                                     175 (58%)
  1                                                     96 (32%)
  2                                                     29 (10%)
  **Primary tumour site**                               
  Intrahepatic                                          157 (52%)
  Extrahepatic                                          64 (21%)
  Gallbladder                                           53 (18%)
  Ampullary                                             26 (9%)
  **Surgery for primary tumour**                        
  Yes                                                   167 (56%)
  No                                                    133 (44%)
  **Previous adjuvant CT**                              
  Yes                                                   61 (20%)
  No                                                    230 (77%)
  Not reported                                          9 (3%)
  **Previous adjuvant radiotherapy**                    
  Yes                                                   20 (7%)
  No                                                    267 (89%)
  Not reported                                          13 (4%)
  **Number of metastatic sites**                        
  Median                                                2
  Range                                                 1--5
  **Liver metastases**                                  
  Yes                                                   250 (83%)
  No                                                    50 (17%)
  **Lung metastases**                                   
  Yes                                                   92 (31%)
  No                                                    208 (69%)
  **Peritoneal metastases**                             
  Yes                                                   95 (32%)
  No                                                    205 (68%)
  **Bone metastases**                                   
  Yes                                                   31 (10%)
  No                                                    269 (90%)
  **Extent of disease**                                 
  Locally advanced                                      38 (13%)
  Metastatic                                            262 (87%)
  **First-line CT regimen**                             
  Gemcitabine+platinum                                  191 (64%)
  Gemcitabine+fluoropyrimidine                          30 (10%)
  Other gemcitabine-containing regimens                 1 (\<1%)
  Gemcitabine monotherapy                               43 (14%)
  Other                                                 35 (12%)
  **Best objective response with first-line CT**        
  Complete response                                     5 (1%)
  Partial response                                      50 (17%)
  Stable disease                                        123 (41%)
  Progressive disease                                   113 (38%)
  Not reported                                          9 (3%)
  Median PFS with first-line CT (months)                6.0
  **Second-line CT regimen**                            
  Platinum-based                                        96 (32%)
  Gemcitabine+fluoropyrimidine                          44 (15%)
  Gemcitabine monotherapy                               22 (7%)
  Fluoropyrimidine monotherapy                          74 (25%)
  Irinotecan-containing regimens                        22 (7%)
  Taxane-containing regimens                            11 (4%)
  Other                                                 31 (10%)
  **Complete blood coun**t                              
  WBC count \>10 000 mm^−3^                             51 (17%)
  Haemoglobin \<12 g dl^−1^                             133 (44%)
  Platelet count \>400 000 mm^−3^                       20 (7%)
  **Blood chemistry**                                   
  Alkaline phosphatase, U l^−1^ (median, range)         247 (36--1676)
  ALT, U l^−1^ (median, range)                          34 (5--503)
  AST, U l^−1^ (median, range)                          35 (12--279)
  Total bilirubin, mg dl^−1^ (median, range)            0.66 (0.20--8.00)
  Albumin, g dl^−1^ (median, range)                     3.56 (2.00--4.58)
  Carcinoembrionic antigen, ng ml^−1^ (median, range)   5 (0--1497)
  CA19.9, U ml^−1^ (median, range)                      152 (0.5--104136)

Abbreviations: AST=aspartate aminotransferase; ALT=alanine aminotransferase; CT=chemotherapy; ECOG=Eastern Cooperative Oncology Group; *N*=number; PFS=progression-free survival; WBC=white blood cell.

###### Multivariate analysis

                                       **HR**     **95% CI**   ***P*-value**
  ------------------------------------ -------- -------------- ---------------
  PFS after first-line CT ⩾6 months    0.633     0.422--0.949  0.027
  Previous surgery on primary tumour   0.609     0.392--0.945  0.027
  Pretreatment CA19.9 ⩽152 U ml^−1^    0.574     0.370--0.891  0.013
  ECOG performance status 0            0.348     0.215--0.562  \<0.001

Abbreviations: CI=confidence interval; CT=chemotherapy; ECOG=Eastern Cooperative Oncology Group; HR=hazard ratio; PFS=progression-free survival.
